---
title: "flexsurv (R package): papers citing this CRAN package"
description: "6 papers in the tracked journals link to flexsurv (R package) in their Crossref records, the first in 2019; most of them (2) in 2021."
url: https://scholar4ai.com/code/cran-flexsurv
markdown_url: https://scholar4ai.com/code/cran-flexsurv.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "6 papers in the tracked journals link to flexsurv (R package) in their Crossref records, the first in 2019; most of them (2) in 2021. (as of 2026-11-03)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-11-03T14:43:26+09:00
window: 2026-10-05 to 2026-11-03
source: OpenAlex (CC0)
---

# flexsurv (R package): papers linking to it

Research papers in the 480 tracked journals that link to flexsurv (R package) (https://CRAN.R-project.org/package=flexsurv), read from their Crossref records: by year, category and journal, the family tree of papers building on one another, and the linked repositories derived from it or that it derives from.

- CRAN
- https://CRAN.R-project.org/package=flexsurv

All repositories: https://scholar4ai.com/code.md

## Key findings

- 6 papers in the tracked journals link to flexsurv (R package) in their Crossref records, the first in 2019; most of them (2) in 2021.
- By category: Health Economics and Policy (6); the journals with the most are PharmacoEconomics (3), Applied Health Economics and Health Policy (2) and PharmacoEconomics - Open (1).

## By year

*Papers linking to flexsurv (R package) by publication year*

| Year | Papers |
|---|---:|
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |

## Journals

*Journals whose papers link to flexsurv (R package) most*

| Journal | Papers |
|---|---:|
| [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 3 |
| [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2 |
| [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 1 |

## Papers

*Papers linking to flexsurv (R package), most cited first*

| Published | Title | Journal | Authors | Citations | Link |
|---|---|---|---|---:|---|
| 2019-06-20 | [Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States](https://doi.org/10.1007/s40273-019-00812-6) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Thomas E. Delea, Xinke Zhang, Jordan Amdahl et al. | 28 | cites it |
| 2021-05-17 | [Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective](https://doi.org/10.1007/s40273-021-01028-3) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Daniel Stellato, Marroon E. Thabane, David Chandiwana et al. | 7 | cites it |
| 2021-06-09 | [Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective](https://doi.org/10.1007/s40273-021-01027-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | Daniel Stellato, Marroon E. Thabane, Jinhee Park et al. | 7 | cites it |
| 2023-08-22 | [Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia](https://doi.org/10.1007/s40258-023-00826-4) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | Martin Vu, Koen Degeling, Ella R. Thompson et al. | 3 | cites it |
| 2024-05-21 | [Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit](https://doi.org/10.1007/s40258-024-00884-2) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | Dominic Muston | 3 | cites it |
| 2026-10-02 | [Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer Perspective](https://doi.org/10.1007/s41669-026-00674-7) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | Dina Soliman, Christine Brezden‐Masley, Sandeep R. Sehdev et al. | 0 | cites it |

## How this is measured

Links are read from each paper's Crossref record as its publisher deposited it: the URLs and repository DOIs in its reference list (the software and data it cites) and its supplementary links (“is-supplemented-by”: its own code or data). A paper that gives its code only in the text, a footnote or a data availability statement is not counted, and some publishers deposit reference lists without their URLs, so every count here is a lower bound. Repository details come from the GitHub REST API (stars, forks, and the repository a fork was made from), the Hugging Face Hub API (likes, downloads, and the base model a model was derived from) and DataCite (Zenodo and other data DOIs, and the GitHub release a Zenodo record archives), read again every month.

## Cite this page

Scholar4AI. (2026). flexsurv (R package): papers linking to it. Journal and Conference Research Rankings. Retrieved November 3, 2026, from https://scholar4ai.com/code/cran-flexsurv

```bibtex
@misc{scholar4ai-code-cran-flexsurv,
  author = {{Scholar4AI}},
  title = {flexsurv (R package): papers linking to it},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/code/cran-flexsurv}},
  urldate = {2026-11-03},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).